APA
Velasco-Loyden G., Pérez-Carreón J. I., Agüero J. F. C., Romero P. C., Vidrio-Gómez S., Martínez-Pérez L., Yáñez-Maldonado L., Hernández-Muñoz R., Macías-Silva M. & de Sánchez V. C. (20101105). Prevention of in vitro hepatic stellate cells activation by the adenosine derivative compound IFC305. : Biochemical pharmacology.
Chicago
Velasco-Loyden Gabriela, Pérez-Carreón Julio Isael, Agüero José Fernando Cabello, Romero Pilar Cabrales, Vidrio-Gómez Susana, Martínez-Pérez Lidia, Yáñez-Maldonado Lucia, Hernández-Muñoz Rolando, Macías-Silva Marina and de Sánchez Victoria Chagoya. 20101105. Prevention of in vitro hepatic stellate cells activation by the adenosine derivative compound IFC305. : Biochemical pharmacology.
Harvard
Velasco-Loyden G., Pérez-Carreón J. I., Agüero J. F. C., Romero P. C., Vidrio-Gómez S., Martínez-Pérez L., Yáñez-Maldonado L., Hernández-Muñoz R., Macías-Silva M. and de Sánchez V. C. (20101105). Prevention of in vitro hepatic stellate cells activation by the adenosine derivative compound IFC305. : Biochemical pharmacology.
MLA
Velasco-Loyden Gabriela, Pérez-Carreón Julio Isael, Agüero José Fernando Cabello, Romero Pilar Cabrales, Vidrio-Gómez Susana, Martínez-Pérez Lidia, Yáñez-Maldonado Lucia, Hernández-Muñoz Rolando, Macías-Silva Marina and de Sánchez Victoria Chagoya. Prevention of in vitro hepatic stellate cells activation by the adenosine derivative compound IFC305. : Biochemical pharmacology. 20101105.